guest ::
| Home > Publications Database > Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease. > print |
| Home > Publications Database > Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease. > print |
| 001 | 279047 | ||
| 005 | 20250713001353.0 | ||
| 024 | 7 | _ | |a 10.1016/j.molmet.2025.102163 |2 doi |
| 024 | 7 | _ | |a pmid:40345387 |2 pmid |
| 024 | 7 | _ | |a altmetric:177021123 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-00677 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a de Mello, Natalia Prudente |b 0 |
| 245 | _ | _ | |a Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease. |
| 260 | _ | _ | |a Oxford [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1749559618_9055 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Parkinson's disease (PD) is recognized as a systemic condition, with clinical features potentially modifiable by dietary intervention. Diets high in saturated fats and refined sugars significantly increase PD risk and exacerbate motor and non-motor symptoms, yet precise metabolic mechanisms are unclear. Our objective here was to investigate the interplay between diet and PD-associated phenotypes from a metabolic perspective.We explored PARK7 KO mice under chronic glycative stress induced by prolonged high-fat high-sucrose (HFHS) diet. We investigated metabolic consequences by combining classical metabolic phenotyping (body composition, glucose tolerance, indirect calorimetry, functional assays of isolated mitochondria) with metabolomics profiling of biospecimens from mice and PD patients.We found this obesogenic diet drives loss of fat and muscle mass in early-onset PD mice, with a selective vulnerability of glycolytic myofibers. We show that PD mice and early-onset familial PD patients are under pervasive glycative stress with pathological accumulation of advanced glycation end products (AGEs), including N-α-glycerinylarginine (α-GR) and N-α-glycerinyllysine (α-GK), two previously unknown glycerinyl-AGE markers.Our results offer the first proof for a direct link between diet, accumulation of AGEs and genetics of PD. We also expand the repertoire of clinically-relevant glycative stress biomarkers to potentially define at-risk patients before neurological or metabolic symptoms arise, and/or to monitor disease onset, progression, and effects of interventions. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Advanced glycation endproducts (AGEs) |2 Other |
| 650 | _ | 7 | |a Biomarkers |2 Other |
| 650 | _ | 7 | |a Glycative stress |2 Other |
| 650 | _ | 7 | |a Glycobiology |2 Other |
| 650 | _ | 7 | |a Muscle atrophy |2 Other |
| 650 | _ | 7 | |a Parkinson's disease |2 Other |
| 650 | _ | 7 | |a Glycation End Products, Advanced |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: metabolism |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Diet, High-Fat: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Muscular Atrophy: metabolism |2 MeSH |
| 650 | _ | 2 | |a Mice, Knockout |2 MeSH |
| 650 | _ | 2 | |a Glycation End Products, Advanced: metabolism |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a Metabolomics: methods |2 MeSH |
| 650 | _ | 2 | |a Muscle, Skeletal: metabolism |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 700 | 1 | _ | |a Berger, Michelle Tamara |b 1 |
| 700 | 1 | _ | |a Lagerborg, Kim A |b 2 |
| 700 | 1 | _ | |a Yan, Yingfei |b 3 |
| 700 | 1 | _ | |a Wettmarshausen, Jennifer |b 4 |
| 700 | 1 | _ | |a Keipert, Susanne |b 5 |
| 700 | 1 | _ | |a Weidner, Leopold |b 6 |
| 700 | 1 | _ | |a Tokarz, Janina |b 7 |
| 700 | 1 | _ | |a Möller, Gabriele |b 8 |
| 700 | 1 | _ | |a Ciciliot, Stefano |b 9 |
| 700 | 1 | _ | |a Walia, Safal |b 10 |
| 700 | 1 | _ | |a Cheng, Yiming |b 11 |
| 700 | 1 | _ | |a Chudenkova, Margarita |b 12 |
| 700 | 1 | _ | |a Artati, Anna |b 13 |
| 700 | 1 | _ | |a Weisenhorn, Daniela Vogt |b 14 |
| 700 | 1 | _ | |a Wurst, Wolfgang |0 P:(DE-2719)2000028 |b 15 |u dzne |
| 700 | 1 | _ | |a Adamski, Jerzy |b 16 |
| 700 | 1 | _ | |a Nilsson, Roland |b 17 |
| 700 | 1 | _ | |a Cossu, Giovanni |b 18 |
| 700 | 1 | _ | |a Boon, Agnita |b 19 |
| 700 | 1 | _ | |a Kievit, Anneke |b 20 |
| 700 | 1 | _ | |a Mandemakers, Wim |b 21 |
| 700 | 1 | _ | |a Bonifati, Vincenzo |b 22 |
| 700 | 1 | _ | |a Jain, Mohit |b 23 |
| 700 | 1 | _ | |a Jastroch, Martin |b 24 |
| 700 | 1 | _ | |a Schmitt-Kopplin, Philippe |b 25 |
| 700 | 1 | _ | |a Perocchi, Fabiana |b 26 |
| 700 | 1 | _ | |a Dyar, Kenneth Allen |b 27 |
| 773 | _ | _ | |a 10.1016/j.molmet.2025.102163 |g Vol. 97, p. 102163 - |0 PERI:(DE-600)2708735-9 |p 102163 |t Molecular metabolism |v 97 |y 2025 |x 2212-8778 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/279047/files/DZNE-2025-00677.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/279047/files/DZNE-2025-00677.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:279047 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2000028 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-06 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL METAB : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:49:42Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:49:42Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:49:42Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL METAB : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)1140001 |k AG Wurst |l Genome Engineering |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1140001 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|